Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study

BACKGROUND. In the phase III CORRECT trial, regorafenib significantly improved survival in treatment‐refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization. METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Van Cutsem, Eric, Martinelli, Erika, Cascinu, Stefano, Sobrero, Alberto, Banzi, Maria, Seitz, Jean‐François, Barone, Carlo, Ychou, Marc, Peeters, Marc, Brenner, Baruch, Hofheinz, Ralf Dieter, Maiello, Evaristo, André, Thierry, Spallanzani, Andrea, Garcia‐Carbonero, Rocio, Arriaga, Yull E., Verma, Udit, Grothey, Axel, Kappeler, Christian, Miriyala, Ashok, Kalmus, Joachim, Falcone, Alfredo, Zaniboni, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369948/
https://ncbi.nlm.nih.gov/pubmed/30190299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0072
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados